Calendar | For Your Patients | PHA Main Site | Contact Us | About Us | Not a registered user? Sign up here.

Resource Library

A Long-acting Prostacyclin Agonist with Thromboxane Inhibitory Activity for Pulmonary Hypertension

Masaharu Kataoka

Toru Satoh

N. Nagaya

S. Ogawa

Reviews

  Sign in to add a review

0 comments
Leave a Comment

Conference: 2008 International PHA Conference and Scientific Sessions

Release Date: 06.20.2008

Presentation Type: Abstracts

Kataoka M.1,2, Satoh T.1, Nagaya N.2, Ogawa S.1

1. Cardiopulmonary Division, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
2. Department of Regenerative Medicine and Tissue Engineering, National Cardiovascular Center Research Institute, Osaka, Japan

BACKGROUND: The balance between prostacyclin and thromboxane plays an important role in the regulation of pulmonary vascular tone. Recently, we developed ONO-1301, a novel long-acting prostacyclin agonist with thromboxane synthase inhibitory activity. We investigated whether modulation of prostacyclin/thromboxane balance by ONO-1301 ameliorates monocrotaline-induced pulmonary hypertension in rats.

METHODS: After subcutaneous injection of monocrotaline or vehicle, rats were randomized to receive repeated subcutaneous administration of ONO-1301 or vehicle twice a day for three weeks.

RESULTS: There was significant development of pulmonary hypertension three weeks after monocrotaline injection. Treatment with ONO-1301 significantly attenuated the increases in right ventricular systolic pressure and ratio of right ventricular weight to body weight in monocrotaline rats. Furthermore, ONO-1301 significantly attenuated the increase in medial wall thickness of peripheral pulmonary arteries in monocrotaline rats. The half life of plasma ONO-1301 concentration after a single subcutaneous administration was approximately 5.6 hours. A single administration of ONO-1301 increased plasma cyclic adenosine 3’, 5’-monophosphate level, which lasted at least up to 8 hours. Treatment with ONO-1301 significantly decreased plasma 11-dehydro-thromboxane B2, a metabolite of thromboxane, in monocrotaline rats. Finally, Kaplan-Meier survival curves demonstrated that repeated administration of ONO-1301 improved survival rate in monocrotaline rats compared with vehicle administration (80% vs. 30% in 6-week survival).

CONCLUSIONS: Subcutaneous administration of a novel prostacyclin agonist (ONO-1301) markedly attenuated monocrotaline-induced pulmonary hypertension and improved survival in rats. The beneficial effects of ONO-1301 may occur through its long-lasting stimulation of cyclic adenosine 3’, 5’-monophosphate and inhibition of thromboxane synthase.